



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: University of Otago

Appl. No. 10/561,119

Filed: December 15, 2005

For: ASSESSMENT OF SKELETAL GROWTH
USING MEASUREMENTS OF NT-CNP PEPTIDES

§ Attorney Docket No.: 36697.17
 §
 § Group Art Unit: Unknown
 §
 § Examiner: Unknown
 §
 §
 §

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
 Commissioner For Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in numerical order and are not in any order based on their pertinence.

This Information Disclosure Statement is being filed within three months of the United States filing date or before the mailing date of a first Office Action on the merits. No certification or fee is required (37 CFR §1.97(b)).

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account 08-1394, order number 36697.17.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

Mark D. Moore, Ph.D.
 Registration No. 42,903

Date: 2/2/06
 HAYNES AND BOONE, LLP
 901 Main Street, Suite 3100
 Dallas, Texas 75202-3789
 Telephone: 713-547-2040
 Facsimile: 214-200-0853
 File: 36697.17
 H-593117

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 02-02-06.

Blanca Ramos
 Printed Name

Signature

In place of PTO-1449 Form	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/561,119
		Filing Date	12/15/2005
		Applicant(s)	University of Otago
		Art Unit	Unknown
		Examiner Name	Unknown
SHEET	1	OF	1
		Attorney Docket Number	36697.17

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code – Number – Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N
	A1	WO01/14885 A2	03-01-2001	Biomedica Gesellschaft MBH	No
NON-PATENT LITERATURE DOCUMENTS					
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item, date, page(s), volume-issue number(s), publisher, city/country where published			
	B1	CHUSHO <i>et al.</i> , "Dwarfism and Early Death in Mice Lacking C-Type Natriuretic Peptide," <i>Proc. Natl. Acad. Sci. USA</i> , 98 (7):4016-4021, March 27, 2001.			
	B2	DESAI MEENA, "Growth Disorders," <i>Med. J. Armed Forces Ind.</i> , 59 (4):278-282, 2003.			
	B3	HAMA <i>et al.</i> , "A Monoclonal Antibody to C-Type Natriuretic Peptide – Preparation and Application to Radioimmunoassay and Neutralization Experiment," <i>J. Endocrinology</i> , 141 :473-479, 1994.			
	B4	HARLOW <i>et al.</i> , "Immunizations," <i>Antibodies: A Laboratory Manual</i> , Cold Springs Harbor Laboratory, 53-137, 1988.			
	B5	HUSE <i>et al.</i> , "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> , 246 :1275-1281, December 8, 1989.			
	B6	KOHLE <i>et al.</i> , "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> , 256 (5517): 495-497, August 7, 1975.			
	B7	PRICKETT <i>et al.</i> , "Identification of Amino-Terminal Pro-C-Type Natriuretic Peptide in Human Plasma," <i>Biochemical and Biophysical Research Communications</i> , 286 (3):513-517, 2001.			
	B8	RASAT <i>et al.</i> , "IGF-1 and IGFBP-3 Screening for Disorders of Growth Hormone Secretion," <i>NZ Med. J.</i> , 109 : 156-159, May 10, 1996.			
	B9	STEPAN <i>et al.</i> , "Expression of C-Type Natriuretic Peptide in Human Placenta and Myometrium in Normal Pregnancies and Pregnancies Complicated by Intrauterine Growth Retardation," <i>Fetal Diagn. Ther.</i> , 17 :37-41, 2002.			
	B10	TANNER <i>et al.</i> , "Clinical Longitudinal Standards for Height and Height Velocity for North American Children," <i>J. Pediatrics</i> , 107 (3):317-329, September 1985.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.